TransMedics Group (NASDAQ:TMDX) Given New $130.00 Price Target at Stifel Nicolaus

TransMedics Group (NASDAQ:TMDX) had its target price increased by Stifel Nicolaus from $115.00 to $130.00 in a research note published on Monday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Morgan Stanley increased their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $152.33.

TransMedics Group Stock Up 4.0%

TMDX stock opened at $134.77 on Monday. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 27.50 and a beta of 1.98. TransMedics Group has a 1-year low of $62.23 and a 1-year high of $156.00. The firm has a fifty day moving average price of $135.58 and a two-hundred day moving average price of $127.08. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59.

Insider Activity

In other TransMedics Group news, insider Anil P. Ranganath sold 864 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the sale, the insider directly owned 13,091 shares in the company, valued at approximately $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 2,966 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the completion of the sale, the insider directly owned 29,831 shares of the company’s stock, valued at $4,150,088.72. The trade was a 9.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock valued at $2,353,002 over the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after buying an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after acquiring an additional 322,353 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after acquiring an additional 2,903 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after acquiring an additional 223,409 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.